The visionary and avant-garde Paill Laboratorios created a strategic alliance with the Indian Laboratory CIPLA, the second strongest and most important in India, to distribute and market 6 innovative medicines for the treatment of asthma in El Salvador and Honduras.
CIPLA is a prominent Indian pharmaceutical company, founded in 1935 by Khwaja Abdul Hamied, with its headquarters in Bombay, India.
CIPLA has a global presence and is also known for its technological innovation. It was the first Laboratory in India to receive FDA certification.
CIPLA , Respiratory leader in India with more than 70% of the market share, has a worldwide presence in more than 180 countries and, today, arrives in El Salvador, in partnership with Paill Laboratories, with medicines: Seroflo 125 (Salmeterol and Fluticasone Propionate), Seroflo 250 (Salmeterol and Fluticasone Propionate), Flohale 125 (Fluticasone Propionate,) > Beclate 250 (Beclomethasone Dipropionate) Asthalin (Salbutamol) and Respihaler (Levosalbutamol).
According to data from the World Health Organization - WHO -, currently 235 million people suffer from asthma, which is the most frequent chronic disease in children.
The arrival of CIPLA Laboratories to the country is not only a new and more accessible option for patients of the disease, but also a prestigious and world-class pharmaceutical company has set eyes on our country, for grant him the distribution and commercialization of his medicines in El Salvador and Honduras.
Go to www.ciplamed.com to register and have access to clinical studies in the area of Pulmonology.